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Fig 1. Benign lymphangioendothelioma. Vascular spaces
within the deep dermis demonstrate a slit-like appearance.
(Hematoxylin-eosin stain; original magnification: 3200.)
Fig 2. Benign lymphangioendothelioma. Light brown
papules coalescing into a 5- 3 6-cm plaque on the
patient’s medial left thigh.
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Sirolimus-associated regression of benign
lymphangioendothelioma
To the Editor: Benign lymphangioendothelioma (BL,
acquired progressive lymphangioma) is a rare,
slowly growing lymphatic neoplasm with wide
age distribution appearing most commonly in
middle-aged and older adults. BL typically presents
as an asymptomatic, well-circumscribed plaque with
red to bruise-like coloration on which small papules
may arise. BL most often occurs on the thigh
(33%), but has also appeared on the head and
neck (20.5%), upper limb (20.5%), trunk (18%),
and shoulder (8%).1
Histologically, BL demonstrates anastomosing,
cleft-like, thin-walled vascular channels dissecting
through collagen bundles.1,2 The vascular spaces
may isolate preexisting vascular or adnexal
structures resembling the promontory sign seen in
patch stage Kaposi sarcoma. The vessels are lined by
Open access under CC BY-NC-ND license.a monolayer of endothelial cells with no cytologic
atypia or increased mitoses. Papillary projections
resembling endothelial hyperplasia are sometimes
noted. D2-40epositive immunofluorescence indi-
cates the lymphatic cell origin of BL.2 Recent findings
have shown that vascular endothelial growth factor
(VEGF), a well-known angiogenic growth factor,
promotes lymphogenesis by upregulating mamma-
lian target of rapamycin (mTOR)/p70S6K signaling
and therefore may play a role in the development of
BL.3 BL treatment has typically been limited to
surgical excision for small lesions, although disease
recurrence is common.1
A 48-year-old man who had undergone allograft
kidney transplantation at age 38 presented for
evaluation of a large, slowly growing plaque on his
left thigh which was present since childhood. Since
transplantation, he had been on an immuno-
suppression regimen of tacrolimus, mycophenolate
mofetil, and prednisone. During this period, the
plaque enlarged substantially, prompting his initial
visit to a dermatologist. On examination, dusky
brown to bluish-red dermal papules coalesced into
a 10-3 10-cm plaque overlying his medial left thigh.
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irregular vascular spaces involving the entire dermis.
These spaces had a lobular arrangement superficially
and a more slit-like appearance deeper in the
dermis (Fig 1). No endothelial cell atypia was
present and HHV-8 polymerase chain reaction
was negative. The biopsy was reviewed by 4
board-certified dermatopathologists, including a
vascular expert in consultation, and the diagnosis
of BL was confirmed.
Before the patient’s diagnostic biopsy, his
transplant team suspected Kaposi sarcoma, given
the clinical appearance of the plaque. Given the
team’s clinical experience demonstrating slowed
Kaposi sarcoma disease progression in some cases,
sirolimus was empirically substituted for tacrolimus.
Even though the patient’s diagnosis was ultimately
confirmed as BL, sirolimus was continued because
the thigh plaque improved clinically. After 7.5
months, the patient’s lesion had decreased in size,
stabilized at 5 3 6 cm, lightened in color, and
flattened significantly (Fig 2).
Other reports have demonstrated the efficacy
of this drug in the treatment of lymphovascular
proliferative disorders such as Kaposiform
hemangioendothelioma and diffuse lymphangioma-
tosis.4,5 Evidence suggests that VEGF plays a role in
lymphogenesis by upregulating mTOR signaling.
Recent studies have shown that sirolimus
inhibits lymphogenesis by decreasing synthesis
and promoting degradation of VEGF receptor 3
(VEGFR-3).3 Taken together, these findings suggest
that, by targeting VEGFR-3, sirolimus may
represent an important therapeutic option for
patients with symptomatic BL and, importantly,
other lymphovascular proliferations with malignant
or life-threatening potential.
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superficial granulomatous pyoderma of the
head and neck
To the Editor: Superficial granulomatous pyoderma
(SGP) is a rare, chronic inflammatory disorder.1
Although considered a superficial, vegetative variant
of pyoderma gangrenosum (PG), SGP exhibits
important differences (Fig 1, A).1,2 Moreover, SGP
responds favorably to therapy, except in cases of
SGP involving the head and neck.1 We present a
patient with SGP on the face, neck, and trunk treated
with combined infliximab and topical tacrolimus,
and review all systemic therapies reported, to our
knowledge, in the treatment of SGP of the head and
neck.
An 83-year-old Caucasian man with extensive
history of cardiovascular disease presented for
nonhealing ulcers of more than 1 year’s duration
on the right temple, right postauricular neck, and
central chest (Fig 1, B). Each lesion evolved after a
surgical procedure as slowly growing ulcerative
plaques for whichmultiple therapies were attempted
but unsuccessful, including surgical debridement,
skin grafting, and hyperbaric oxygen. The patient
was on oral prednisone 20 mg daily upon
presentation in early November 2010 and had
failed several oral antibiotics. Prior biopsies of the
right temple and chest were read by an outside
